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Abstract
The International Mouse Phenotyping Consortium (IMPC) continues to expand the catalogue of mammalian gene function 
by conducting genome and phenome-wide phenotyping on knockout mouse lines. The extensive and standardized phenotype 
screens allow the identification of new potential models for human disease through cross-species comparison by computing 
the similarity between the phenotypes observed in the mutant mice and the human phenotypes associated to their orthologous 
loci in Mendelian disease. Here, we present an update on the novel disease models available from the most recent data release 
(DR10.0), with 5861 mouse genes fully or partially phenotyped and a total number of 69,982 phenotype calls reported. 
With approximately one-third of human Mendelian genes with orthologous null mouse phenotypes described, the range 
of available models relevant for human diseases keeps increasing. Among the breadth of new data, we identify previously 
uncharacterized disease genes in the mouse and additional phenotypes for genes with existing mutant lines mimicking the 
associated disorder. The automated and unbiased discovery of relevant models for all types of rare diseases implemented by 
the IMPC constitutes a powerful tool for human genetics and precision medicine.
The role of the IMPC in deciphering gene 
function and human disease
The IMPC aims to characterize the function of every protein 
coding gene and use the phenotypic information obtained 
through extensive phenotyping protocols to identify new 
models for human disease through cross-species (mouse-
to-human) comparison. Frequent data releases are made 
publicly available for the research community, and the sys-
tematic comparison of phenotype abnormalities observed 
in the mouse with those clinical phenotypes described in 
humans allows for the automatic identification of suitable 
disease models. As the IMPC phenotyping screen expands 
to new gene knockout strains and novel gene–disease asso-
ciations and further and improved phenotypes are reported, 
the potential for the IMPC to discover new models for Men-
delian disease increases accordingly.
This comprehensive, standardized phenotyping screen is 
designed to identify and characterize phenotypic abnormali-
ties associated to each gene knockout. The subsequent analy-
sis provides novel insight into mammalian gene function 
and leads to the identification of potential genes involved 
in specific biological systems, e.g. auditory dysfunction 
(Bowl et al. 2017), abnormalities of metabolism (Rozman 
et al. 2018) or ophthalmic disease (Moore et al. 2018). Just 
as importantly, genes with pleiotropic effects across physi-
ological systems are being described, a phenomenon which 
has proved to be abundant in common complex traits (Siva-
kumaran et al. 2011; Gratten and Visscher 2016) and of 
particular relevance in congenital disorders (Ittisoponpisan 
et al. 2017).
High-throughput viability screens are also being per-
formed, enabling the identification of genes essential for 
survival in the mouse, again substantially improving our 
understanding of congenital diseases (Dickinson et al. 2016). 
A first extensive report on novel mouse models for known 
Mendelian disorders from the IMPC has been previously 
published (Meehan et al. 2017). This analysis was based 
on 3328 gene knockouts characterized through the IMPC 
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pipeline (Data Release 5.0; August 2016). A total of 360 
disease models were identified, revealing that approximately 
20% of mouse–human orthologs associated to rare disorders 
showed phenotypic overlap with the human disease accord-
ing to the automated PhenoDigm algorithm (Smedley et al. 
2013), with this percentage increasing to 40% when embry-
onic and neonatal lethal phenotypes were considered.
During the last year, frequent data releases have been 
made publicly available through the IMPC website, with 
5861 mouse genes fully or partially phenotyped to date (DR 
10.0; March 2019). A total number of 69,982 phenotype 
calls are reported, resulting in 4736 gene knockouts with 
at least one phenotypic abnormality detected through the 
early adult phenotyping pipeline or the viability primary 
(postnatal) and secondary (embryonic) screens. Once we 
obtain the corresponding mouse-to-human orthologs, we 
can observe that approximately 1/3 of those genes (1484) 
are associated with rare monogenic diseases as described 
in the OMIM (Amberger et al. 2019) and Orphanet (Rath 
et al. 2012) databases, a 67% increase since the first report 
on disease models was published (Meehan et al. 2017) and 
covering approximately one-third of the known Mendelian 
disease genes (Fig. 1).
From mouse phenotypes to models 
of disease
The mouse phenotypic data collected by the IMPC are 
integrated with human disease resources using automated, 
phenotype similarity calculations. Once we have a set of 
significant phenotypic abnormalities associated with each 
gene (encoded as Mammalian Phenotype Ontology terms 
(MP; Smith and Eppig 2015), we can compare how similar 
they are with respect to the human (clinical) phenotypes, 
encoded by the Human Phenotype Ontology (HPO; Köhler 
Fig. 1  Evolution of the number of genes with null mutant mice pro-
duced and phenotyped by the IMPC over the last years. a Number 
of knockout genes with significant phenotype associations and the 
corresponding number of genes with human orthologs associated 
with disease according to OMIM or ORPHANET resources. b Time 
between data releases and number of IMPC genes with a phenotype 
and orthology to a known human disease gene
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et al. 2019), reported for the disorder associated to the 
human ortholog of that gene.
This phenotypic similarity is computed by several algo-
rithms developed by the Monarch Initiative (Mungall et al. 
2017). Firstly, we need to make the two ontologies compa-
rable by correlating every MP term with the correspond-
ing HPO term. Secondly, we compute a score which give 
us the similarity for each HPO–MP phenotypic match. The 
PhenoDigm algorithm (Smedley et al. 2013) uses all the 
individual scores for each HPO–MP association, taking into 
account the proximity of the two terms in the ontology and 
the frequency of the phenotype in common from the overall 
mouse and disease annotations. It finally produces a per-
centage score by comparing these results to the best pos-
sible score (a mouse model perfectly matching the disease). 
This score allows for the automated identification of mouse 
models of disease.
When we analyzed the data from the latest release (DR 
10.0; March 2019), we identified 1484 mouse knockouts 
with significant phenotype annotations whose human 
ortholog is associated to disease. For a small percentage 
(134, 9.03%), there were no HPO-encoded phenotypes avail-
able for the corresponding disorder, so it was no possible 
to compute the phenotypic similarity and therefore their 
suitability as models for the disease (Fig. 2). One reason 
for this may be that these are very recent gene–disease 
associations or entries in the respective databases and the 
reported phenotypes have not yet been encoded as HPO 
terms. Manual inspection revealed, nonetheless, the mutant 
mouse line is able to mimic some of the disease phenotypes, 
e.g. the homozygous Cfap69 IMPC line has a male infer-
tility phenotype and the human orthologue is associated 
to Spermatogenic failure 24 (OMIM:617959) (Dong et al. 
2018). Another example is the homozygous Cxcr2 line with 
several phenotypes involving B cell and T cell disturbances 
and the corresponding human orthologue CXCR2 associ-
ated to Autosomal recessive, severe congenital neutropenia 
due to CXCR2 deficiency (ORPHA:420699). In some other 
cases, we found that these are gene–phenotype relationships 
reported as susceptibility factors with no associated HPO 
phenotypes available, e.g. {Asthma, susceptibility to, 1} 
(OMIM:607277) and PTGDR, for which the IMPC mouse 
orthologue Ptgdr shows decreased basophil cell number and 
decreased circulating alanine transaminase level.
Considering those other genes with HPO-encoded pheno-
types for the associated disorders, for 735 (49.53%) we did 
not obtained a PhenoDigm match, which indicates that there 
is no phenotype in common between the knockout mouse 
and the disease. This may be explained by several factors, 
including the following: (1) underlying genetic and physi-
ological differences between mouse and human, e.g. those 
regarding gene families, which could lead to paralogous 
genetic redundancy in the mouse, this being the reason why 
the knockout is not able to recapitulate the human phenotype 
(Barbaric et al. 2007); (2) IMPC mouse knockouts are null 
mutants (loss-of-function), whereas disease-causing muta-
tions in humans may have other effects on function (e.g. 
gain-of-function, dominant negative); (3) the phenotype 
screen is not yet completed and the relevant physiological 
systems still need to be evaluated; (4) algorithm limitations 
Fig. 2  Disease-associated genes with phenotypic abnormalities 
described in DR10.0 and potential models for human disease. Disease 
genes: IMPC knockout mice with significant phenotype annotations 
and a human ortholog associated to disease according to OMIM or 
Orphanet; No HPO annotations: No HPO-encoded phenotypes avail-
able for the disorders associated to the gene; HPO annotations: HPO-
encoded phenotypes available for the associated disease; No Pheno-
Digm match: no phenotypic similarity was found between the IMPC 
knockout mouse and the human clinical phenotypes; PhenoDigm 
match: the IMPC null mutant recapitulates at least partially the dis-
ease phenotypes
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to capture the similarity between mammalian and human 
phenotypes; (5) limited coverage of the phenotypic screen-
ing pipeline for certain more specific human phenotypes 
(e.g. intellectual disability-related phenotypes).
For the remaining 615 genes (41.44% of the total set of 
disease-associated genes), the IMPC mouse mimics, at least 
partially, the disease phenotypes. This means an increase 
of 255 mutant strains regarding the number of potentially 
relevant disease models, and a percentage very similar to 
that reported in Meehan et al. (2017) (360/889; 40.49%).
Novel mouse models for human disease
A summary of some new IMPC disease models with respect 
to the previous report is provided in Table 1. These examples 
were selected based on one of two criteria: either they are 
the first mouse mutant reported for that gene [i.e. there is 
no previous mouse model according to the Mouse Genome 
Informatics (MGI) resource (Smith et al. 2017)], or the 
IMPC knockout is able to capture new and relevant disease 
phenotypes.
UPF3B, associated to an X-linked syndromic mental 
retardation (OMIM:300676), illustrates the added value of 
the IMPC for these type of disorders. A previously described 
mouse model shows several neurological and behavioural 
phenotypes. The IMPC null mutant is able to capture 
some of these behavioural phenotypes and, additionally, 
very specific skeletal abnormalities reported in patients. 
Similarly, RAB3GAP2, associated to Martsolf Syndrome 
(OMIM:212720), has no previous mouse mutant produced, 
with the novel IMPC model reflecting the pleiotropy of the 
gene by mimicking cardiovascular, facial/eye and skeletal 
phenotypes.
Other novel disease models reveal phenotypic abnor-
malities restricted to a particular physiological system, 
e.g. HMCN1, linked to age-related Macular Degeneration 
(OMIM:603075), and with several vision/eye phenotype 
associations found in the mouse mutant, including cataract, 
abnormal optic disk morphology as well as an abnormal 
behavioural response to light; or DSG2, associated to Car-
diomyopathy, dilated, 1BB (OMIM:612877) for which the 
ortholog homozygous knockout mouse shows several car-
diovascular phenotypes: decreased cardiac muscle contrac-
tility, dilated heart left ventricle and increased heart weight. 
Another example is MTNR1B, related to noninsulin-depend-
ent Diabetes mellitus (OMIM:125853), and the correspond-
ing IMPC mouse line showing increased fasted circulating 
glucose levels. Finally, an inherited form of pancreatitis, 
Hereditary Chronic Pancreatitis (ORPHA:676), for which 
mutations in CPA1 have been found to be associated with, 
provides another example of a prospective disease model, 
with no previous knockout mouse able to capture the clinical 
phenotypes and the IMPC homozygous mice displaying sev-
eral phenotypes related to pancreatic function, e.g. abnormal 
neutrophil and lymphocyte cell numbers.
Ongoing and future work
Novel gene–phenotype associations covering diverse biologi-
cal systems will continue to be added to the IMPC catalogue to 
complete an encyclopaedia of mammalian gene function. This 
comprises both the completion of partially phenotyped lines 
and the addition of new null mutant mouse strains, providing 
novel and better characterized mouse models. The analysis of 
their phenotypes will enhance the collection of those models 
of particular significance for human disease studies.
Several undergoing projects aim to improve the iden-
tification of relevant mouse models. An embryo imaging 
automated analysis pipeline is being developed, where high-
resolution 3D imaging is used to quantify aberrant morphol-
ogy that could not be determined by gross inspection (Brown 
et al. 2018). This will be crucial for the automatic detec-
tion of embryo abnormalities critical for congenital anoma-
lies and developmental disorders. Moreover, additional 
improvements in the phenotyping screening protocols are 
being made. Such advances include the implementation of a 
late-onset systemic phenotyping (ageing) pipeline, with the 
potential of revealing phenotypes modelling age-related dis-
ease, and also the identification of human phenotype areas 
less covered by the current mouse phenotyping screenings or 
those others which might be more challenging to implement.
To keep the pace with the rapid generation of data from 
the IMPC production and phenotyping centres, the Mouse 
Phenotyping Informatics Infrastructure (MPI2) (Ring et al. 
2015) is performing upgrades to the software and methods 
used for the automated statistical analysis of phenotype data. 
Thus, a new window approach is currently being applied 
to assess the significance of the phenotypic abnormali-
ties observed in the mutant mice. A thorough revision and 
improvement of the phenotype matching algorithms used for 
the identification of relevant disease models is also under-
way. This will allow, for instance, to take full advantage of 
the standardized phenotyping, including accounting for the 
absence of a given phenotype (negative phenotype).
In summary, the comprehensive phenotype screen per-
formed by the IMPC, covering the full range of physiologi-
cal systems, is not focused in any particular disease area. 
This, together with the interspecies comparison of pheno-
types currently implemented, allows the automated, unbi-
ased identification of models for all types of human disease. 
The increasing number of knockout mouse lines available, 
covering up to one-third of known human Mendelian disease 
genes, makes the IMPC catalogue a critical resource for the 
human genetics and precision medicine community.
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Methods
IMPC mouse phenotypes
All the significant phenotype associations from the latest 
and previous data releases are publicly available from the 
IMPC portal.
Files: ALL_genotype_phenotype.csv.gz [Downloaded 
02/05/2019]
Source: ftp://ftp.ebi.ac.uk/pub/databases/impc/
Gene–disease associations
The human genes associated with Mendelian disease were 
obtained from OMIM (Amberger et al. 2019) and Orphanet 
(Rath et al. 2012) databases.
OMIM
Files: mim2gene.txt.gz; morbidmap.txt [Downloaded 
21/03/2019]
Source: https ://www.omim.org/downl oads/
Orphanet
File: en_product6.xml [Downloaded 21/03/2019]
Source: http://www.orpha data.org/cgi-bin/index .php
Human phenotypes
The human clinical phenotypes—encoded as Human Phe-
notype Ontology (HPO) annotations reported for these dis-
orders, were extracted from the HPO portal (Köhler et al. 
2019).
File: phenotype_annotation.tab.gz [Downloaded 
21/03/2019]
Source: http://compb io.chari te.de/jenki ns/job/hpo.annot 
ation s/
Mouse–human orthologues
The mouse–human orthologues were identified from 
Ensembl through BioMart (Hunt et al. 2018) [Ensembl95, 
Downloaded 21/03/2019].
MGI mouse phenotypes
Previously reported mouse phenotypes were obtained from 
the MGI resource (Smith et al. 2017)
Files: MGI_PhenoGenoMP.rpt.gz; MGI_GenePheno.rpt 
[Downloaded 21/03/2019]
Source: http://www.infor matic s.jax.org/downl oads/
repor ts/index .html
Phenotypic similarity
The PhenoDigm algorithm (Smedley et al. 2013) com-
putes individual scores for each HPO–MP phenotypic 
match, based on the proximity of the two terms in the 
overall cross-species ontology (Jaccard index; simJ) and 
the observed frequency of the phenotype in common from 
the entire set of disease and mouse annotations (Infor-
mation Content; IC). The geometric mean of the IC and 
simJ measures was used to generate the HPO–MP pair-
wise score. The overall score, which is a percentage-based 
score, is the result of comparing the best and mean scores 
for all the pairwise HPO–MP comparisons relative to the 
maximum possible scores for a mouse model perfectly 
mimicking the disease phenotypes. The disease models 
as described in this paper: PhenoDigm percentage score 
greater than 0. No PhenoDigm match: PhenoDigm per-
centage score equal to 0, i.e. no single HPO–MP match.
Software
Statistics and figures were generated using R 3.5.1 (R Core 
Team 2018) and the following packages: ggplot2 (Wick-
ham 2016), cowplot (Wilke 2019) and networkD3 (Allaire 
et al. 2017).
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